Moreover, plerixafor, a CXCR4 antagonist, has been demonstrated to optimize the mobilization procedures in patients with NHL and multiple myeloma, due to its capability to enhance the HSC mobilization effect of G-CSF (9–12). The gene discussed is CXCR4; the disease is non-Hodgkin lymphoma.